Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb
PHASE2CompletedINTERVENTIONAL
Enrollment
25
Participants
Timeline
Start Date
June 25, 2015
Primary Completion Date
February 8, 2017
Study Completion Date
February 8, 2017
Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG
Pazopanib
All Listed Sponsors
lead
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
NCT04462445 - Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb | Biotech Hunter | Biotech Hunter